FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Annette Fleckenstein

Research Profile

Chemicals & Drugs

Living Beings

Anatomy

Concepts & Ideas

Drug Dose Response Relationship

Co-author Network

Publications

TOP 3
Christopher L German; Glen R Hanson; Annette E Fleckenstein
Amphetamine and methamphetamine reduce striatal dopamine transporter function without concurrent dopamine transporter relocalization.
Lisa M McFadden; Shannon M Nielsen; Kristen A Stout; Paula L Vieira-Brock; Diana G Wilkins; Scott C Allen; Glen R Hanson; Annette E Fleckenstein
Methamphetamine self-administration acutely decreases monoaminergic transporter function.
Lisa M McFadden; Shannon M Nielsen; Kristen A Stout; Paula L Vieira-Brock; Diana G Wilkins; Scott C Allen; David M Andrenyak; Jonathan D Ellis; Greg C Hadlock; Glen R Hanson; Amanda J Hoonakker; Annette E Fleckenstein
Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Annette Fleckenstein (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Christopher L German; Glen R Hanson; Annette E Fleckenstein
Amphetamine and methamphetamine reduce striatal dopamine transporter function without concurrent dopamine transporter relocalization.
Journal of neurochemistry 2012;123(2):288-97.
2012: Lisa M McFadden; Shannon M Nielsen; Kristen A Stout; Paula L Vieira-Brock; Diana G Wilkins; Scott C Allen; Glen R Hanson; Annette E Fleckenstein
Methamphetamine self-administration acutely decreases monoaminergic transporter function.
Synapse (New York, N.Y.) 2012;66(3):240-5.
2012: Lisa M McFadden; Shannon M Nielsen; Kristen A Stout; Paula L Vieira-Brock; Diana G Wilkins; Scott C Allen; David M Andrenyak; Jonathan D Ellis; Greg C Hadlock; Glen R Hanson; Amanda J Hoonakker; Annette E Fleckenstein
Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure.
The Journal of pharmacology and experimental therapeutics 2012;340(2):295-303.
2011: Paula L Vieira-Brock; Annette E Fleckenstein; Eleanor I Miller; Shannon M Nielsen; Diana G Wilkins
Simultaneous quantification of nicotine and metabolites in rat brain by liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2011;879(30):3465-74.
2011: Gregory C Hadlock; Glen R Hanson; Amanda J Hoonakker; Lisa M McFadden; Paula L Vieira-Brock; Katy M Webb; Diana G Wilkins; Scott C Allen; David M Andrenyak; Pei Wen Chu; Kevin M Conrad; Jonathan D Ellis; Christopher L German; James W Gibb; Annette E Fleckenstein
4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse.
The Journal of pharmacology and experimental therapeutics 2011;339(2):530-6.
2011: Lisa M McFadden; Amanda J Hoonakker; Paula L Vieira-Brock; Kristen A Stout; Nicole M Sawada; Jonathan D Ellis; Scott C Allen; Elliot T Walters; Shannon M Nielsen; James W Gibb; Mario E Alburges; Diana G Wilkins; Glen R Hanson; Annette E Fleckenstein
Methamphetamine treatment during development attenuates the dopaminergic deficits caused by subsequent high-dose methamphetamine administration.
Synapse (New York, N.Y.) 2011;65(8):771-7.
2011: Jonathan D Ellis; Christopher L German; Elisabeth Birdsall; Jarom E Hanson; Marcus A Crosby; Shane D Rowley; Nicole A Sawada; Jeremiah N West; Glen R Hanson; Annette E Fleckenstein
Ephedrine decreases vesicular monoamine transporter-2 function.
Synapse (New York, N.Y.) 2011;65(5):449-51.
2011: Mario E Alburges; Amanda J Hoonakker; Kristen Ashley Horner; Annette E Fleckenstein; Glen R Hanson
Methylphenidate alters basal ganglia neurotensin systems through dopaminergic mechanisms: a comparison with cocaine treatment.
Journal of neurochemistry 2011;117(3):470-8.
2011: Gregory C Hadlock; Chad C Nelson; Anthony J Baucum; Glen R Hanson; Annette E Fleckenstein
Ex vivo identification of protein-protein interactions involving the dopamine transporter.
Journal of neuroscience methods 2011;196(2):303-7.
2011: Paul S Frankel; Amanda J Hoonakker; Mario E Alburges; Jacob W McDougall; Lisa M McFadden; Annette E Fleckenstein; Glen R Hanson
Effect of methamphetamine self-administration on neurotensin systems of the basal ganglia.
The Journal of pharmacology and experimental therapeutics 2011;336(3):809-15.
2010: Pei-Wen Chu; Gregory C Hadlock; Paula Vieira-Brock; Kristen Stout; Glen R Hanson; Annette E Fleckenstein
Methamphetamine alters vesicular monoamine transporter-2 function and potassium-stimulated dopamine release.
Journal of neurochemistry 2010;115(2):325-32.
2010: Gregory C Hadlock; Pei-Wen Chu; Elliot T Walters; Glen R Hanson; Annette E Fleckenstein
Methamphetamine-induced dopamine transporter complex formation and dopaminergic deficits: the role of D2 receptor activation.
The Journal of pharmacology and experimental therapeutics 2010;335(1):207-12.
2009: Trent J Volz; Sarah J Farnsworth; Glen R Hanson; Annette E Fleckenstein
Measurement of plasmalemmal dopamine transport, vesicular dopamine transport, and K(+)-stimulated dopamine release in frozen rat brain tissue.
Journal of neuroscience methods 2009;180(2):317-20.
2009: Jarom E Hanson; Elisabeth Birdsall; Kristi S Seferian; Marcus A Crosby; Kristen A Keefe; James W Gibb; Glen R Hanson; Annette E Fleckenstein
Methamphetamine-induced dopaminergic deficits and refractoriness to subsequent treatment.
European journal of pharmacology 2009;607(1-3):68-73.
2009: Gregory C Hadlock; Anthony J Baucum; Jill L King; Kristen Ashley Horner; Glen A Cook; James W Gibb; Diana G Wilkins; Glen R Hanson; Annette E Fleckenstein
Mechanisms underlying methamphetamine-induced dopamine transporter complex formation.
The Journal of pharmacology and experimental therapeutics 2009;329(1):169-74.
2009: Sarah J Farnsworth; Trent J Volz; Glen R Hanson; Annette E Fleckenstein
Cocaine alters vesicular dopamine sequestration and potassium-stimulated dopamine release: the role of D2 receptor activation.
The Journal of pharmacology and experimental therapeutics 2009;328(3):807-12.
2009: Trent J Volz; Sarah J Farnsworth; Glen R Hanson; Annette E Fleckenstein
Method development and validation of an in vitro model of the effects of methylphenidate on membrane-associated synaptic vesicles.
Journal of neuroscience methods 2009;177(1):177-82.
2009: Annette E Fleckenstein; Trent J Volz; Glen R Hanson
Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications.
Neuropharmacology 2009;56 Suppl 1():133-8.
2008: Trent J Volz; Sarah J Farnsworth; Glen R Hanson; Annette E Fleckenstein
Methylphenidate-induced alterations in synaptic vesicle trafficking and activity.
Annals of the New York Academy of Sciences 2008;1139():285-90.
2008: Trent J Volz; Sarah J Farnsworth; Shane D Rowley; Glen R Hanson; Annette E Fleckenstein
Methylphenidate-induced increases in vesicular dopamine sequestration and dopamine release in the striatum: the role of muscarinic and dopamine D2 receptors.
The Journal of pharmacology and experimental therapeutics 2008;327(1):161-7.
2008: Pei-Wen Chu; Kristi S Seferian; Elisabeth Birdsall; Jannine G Truong; James A Riordan; Cameron Metcalf; Glen R Hanson; Annette E Fleckenstein
Differential regional effects of methamphetamine on dopamine transport.
European journal of pharmacology 2008;590(1-3):105-10.
2007: Trent J Volz; Sarah J Farnsworth; Jill L King; Evan Riddle; Glen R Hanson; Annette E Fleckenstein
Methylphenidate administration alters vesicular monoamine transporter-2 function in cytoplasmic and membrane-associated vesicles.
The Journal of pharmacology and experimental therapeutics 2007;323(2):738-45.
2007: Evan Riddle; Glen R Hanson; Annette E Fleckenstein
Therapeutic doses of amphetamine and methylphenidate selectively redistribute the vesicular monoamine transporter-2.
European journal of pharmacology 2007;571(1):25-8.
2007: Trent J Volz; Glen R Hanson; Annette E Fleckenstein
The role of the plasmalemmal dopamine and vesicular monoamine transporters in methamphetamine-induced dopaminergic deficits.
Journal of neurochemistry 2007;101(4):883-8.
2007: Trent J Volz; Annette E Fleckenstein; Glen R Hanson
Methamphetamine-induced alterations in monoamine transport: implications for neurotoxicity, neuroprotection and treatment.
Addiction (Abingdon, England) 2007;102 Suppl 1():44-8.
2007: Jonathan P Danaceau; Cassandra E Deering; Jayme E Day; Stacy J Smeal; Kamisha L Johnson-Davis; Annette E Fleckenstein; Diana G Wilkins
Persistence of tolerance to methamphetamine-induced monoamine deficits.
European journal of pharmacology 2007;559(1):46-54.
2007: Annette E Fleckenstein; Trent J Volz; Evan Riddle; James W Gibb; Glen R Hanson
New insights into the mechanism of action of amphetamines.
Annual review of pharmacology and toxicology 2007;47():681-98.
2006: Trent J Volz; Glen R Hanson; Annette E Fleckenstein
Kinetic analysis of developmental changes in vesicular monoamine transporter-2 function.
Synapse (New York, N.Y.) 2006;60(6):474-7.
2006: Kristi S Rau; Jannine G Truong; Diana G Wilkins; Annette E Fleckenstein; Glen R Hanson
Age-dependent effects of methamphetamine on VMAT-2.
Annals of the New York Academy of Sciences 2006;1074():154-9.
2006: Kristi S Rau; Elisabeth Birdsall; Trent J Volz; James A Riordan; Anthony J Baucum; Brian P Adair; Rebecca Bitter; James W Gibb; Glen R Hanson; Annette E Fleckenstein
Methamphetamine administration reduces hippocampal vesicular monoamine transporter-2 uptake.
The Journal of pharmacology and experimental therapeutics 2006;318(2):676-82.
2006: Trent J Volz; Glen R Hanson; Annette E Fleckenstein
Measurement of kinetically resolved vesicular dopamine uptake and efflux using rotating disk electrode voltammetry.
Journal of neuroscience methods 2006;155(1):109-15.
2006: Evan Riddle; Annette E Fleckenstein; Glen R Hanson
Mechanisms of methamphetamine-induced dopaminergic neurotoxicity.
The AAPS journal 2006;8(2):E413-8.
2005: Kristi S Rau; Elisabeth Birdsall; Jarom E Hanson; Kamisha L Johnson-Davis; Frank carroll; Diana G Wilkins; James W Gibb; Glen R Hanson; Annette E Fleckenstein
Bupropion increases striatal vesicular monoamine transport.
Neuropharmacology 2005;49(6):820-30.
2005: Jannine G Truong; Diana G Wilkins; Jakub Baudys; Dennis Crouch; Kamisha L Johnson-Davis; James W Gibb; Glen R Hanson; Annette E Fleckenstein
Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: implications for neurotoxicity.
The Journal of pharmacology and experimental therapeutics 2005;314(3):1087-92.
2005: Evan Riddle; Annette E Fleckenstein; Glen R Hanson
Role of monoamine transporters in mediating psychostimulant effects.
The AAPS journal 2005;7(4):E847-51.
2004: Jannine G Truong; Amy H Newman; Glen R Hanson; Annette E Fleckenstein
Dopamine D2 receptor activation increases vesicular dopamine uptake and redistributes vesicular monoamine transporter-2 protein.
European journal of pharmacology 2004;504(1-2):27-32.
2004: Glen R Hanson; Verónica Sandoval; Evan Riddle; Annette E Fleckenstein
Psychostimulants and vesicle trafficking: a novel mechanism and therapeutic implications.
Annals of the New York Academy of Sciences 2004;1025():146-50.
2004: Jannine G Truong; Glen R Hanson; Annette E Fleckenstein
Apomorphine increases vesicular monoamine transporter-2 function: implications for neurodegeneration.
European journal of pharmacology 2004;492(2-3):143-7.
2004: Kamisha L Johnson-Davis; Jannine G Truong; Annette E Fleckenstein; Diana G Wilkins
Alterations in vesicular dopamine uptake contribute to tolerance to the neurotoxic effects of methamphetamine.
The Journal of pharmacology and experimental therapeutics 2004;309(2):578-86.
2004: Anthony J Baucum; Kristi S Rau; Evan Riddle; Glen R Hanson; Annette E Fleckenstein
Methamphetamine increases dopamine transporter higher molecular weight complex formation via a dopamine- and hyperthermia-associated mechanism.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2004;24(13):3436-43.
2004: Glen R Hanson; Kristi S Rau; Annette E Fleckenstein
The methamphetamine experience: a NIDA partnership.
Neuropharmacology 2004;47 Suppl 1():92-100.
2003: Kamisha L Johnson-Davis; Annette E Fleckenstein; Diana G Wilkins
The role of hyperthermia and metabolism as mechanisms of tolerance to methamphetamine neurotoxicity.
European journal of pharmacology 2003;482(1-3):151-4.
2003: Annette E Fleckenstein; Glen R Hanson
Impact of psychostimulants on vesicular monoamine transporter function.
European journal of pharmacology 2003;479(1-3):283-9.
2003: Jannine G Truong; Kristi S Rau; Glen R Hanson; Annette E Fleckenstein
Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson's neurodegeneration.
European journal of pharmacology 2003;474(2-3):223-6.
2003: Yvette V Ugarte; Kristi S Rau; Evan Riddle; Glen R Hanson; Annette E Fleckenstein
Methamphetamine rapidly decreases mouse vesicular dopamine uptake: role of hyperthermia and dopamine D2 receptors.
European journal of pharmacology 2003;472(3):165-71.
2003: Verónica Sandoval; Evan Riddle; Glen R Hanson; Annette E Fleckenstein
Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits.
The Journal of pharmacology and experimental therapeutics 2003;304(3):1181-7.
2003: Evan Riddle; Kristi S Rau; Matthew K Topham; Glen R Hanson; Annette E Fleckenstein
Ceramide-induced alterations in dopamine transporter function.
European journal of pharmacology 2003;458(1-2):31-6.
2002: Ryan R Metzger; Jeffrey M Brown; Verónica Sandoval; Kristi S Rau; Mohamed A Elwan; Gary Miller; Glen R Hanson; Annette E Fleckenstein
Inhibitory effect of reserpine on dopamine transporter function.
European journal of pharmacology 2002;456(1-3):39-43.
2002: Verónica Sandoval; Evan Riddle; Glen R Hanson; Annette E Fleckenstein
Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2002;22(19):8705-10.
2002: Evan Riddle; Matthew K Topham; John W Haycock; Glen R Hanson; Annette E Fleckenstein
Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine.
European journal of pharmacology 2002;449(1-2):71-4.
2002: Jeffrey M Brown; Evan Riddle; Verónica Sandoval; Raul K Weston; Jarom E Hanson; Michael J Crosby; Yvette V Ugarte; James W Gibb; Glen R Hanson; Annette E Fleckenstein
A single methamphetamine administration rapidly decreases vesicular dopamine uptake.
The Journal of pharmacology and experimental therapeutics 2002;302(2):497-501.
2002: Michael J Crosby; Jarom E Hanson; Annette E Fleckenstein; Glen R Hanson
Phencyclidine increases vesicular dopamine uptake.
European journal of pharmacology 2002;438(1-2):75-8.
2002: J Paul Hansen; Evan Riddle; Verónica Sandoval; Jeffrey M Brown; James W Gibb; Glen R Hanson; Annette E Fleckenstein
Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity.
The Journal of pharmacology and experimental therapeutics 2002;300(3):1093-100.
2002: Evan Riddle; Jerry M Kokoshka; Diana G Wilkins; Glen R Hanson; Annette E Fleckenstein
Tolerance to the neurotoxic effects of methamphetamine in young rats.
European journal of pharmacology 2002;435(2-3):181-5.
2001: Jeffrey M Brown; Glen R Hanson; Annette E Fleckenstein
Cocaine-induced increases in vesicular dopamine uptake: role of dopamine receptors.
The Journal of pharmacology and experimental therapeutics 2001;298(3):1150-3.
2001: Jeffrey M Brown; Glen R Hanson; Annette E Fleckenstein
Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants.
The Journal of pharmacology and experimental therapeutics 2001;296(3):762-7.
2001: Verónica Sandoval; Evan Riddle; Yvette V Ugarte; Glen R Hanson; Annette E Fleckenstein
Methamphetamine-induced rapid and reversible changes in dopamine transporter function: an in vitro model.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2001;21(4):1413-9.
2000: Verónica Sandoval; Glen R Hanson; Annette E Fleckenstein
Methamphetamine decreases mouse striatal dopamine transporter activity: roles of hyperthermia and dopamine.
European journal of pharmacology 2000;409(3):265-71.
2000: Ryan R Metzger; HM Haughey; Diana G Wilkins; James W Gibb; Glen R Hanson; Annette E Fleckenstein
Methamphetamine-induced rapid decrease in dopamine transporter function: role of dopamine and hyperthermia.
The Journal of pharmacology and experimental therapeutics 2000;295(3):1077-85.
2000: Jerry M Kokoshka; Annette E Fleckenstein; Diana G Wilkins; Glen R Hanson
Age-dependent differential responses of monoaminergic systems to high doses of methamphetamine.
Journal of neurochemistry 2000;75(5):2095-102.
2000: Annette E Fleckenstein; James W Gibb; Glen R Hanson
Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity.
European journal of pharmacology 2000;406(1):1-13.
2000: HM Haughey; Annette E Fleckenstein; Ryan R Metzger; Glen R Hanson
The effects of methamphetamine on serotonin transporter activity: role of dopamine and hyperthermia.
Journal of neurochemistry 2000;75(4):1608-17.
2000: Jeffrey M Brown; Glen R Hanson; Annette E Fleckenstein
Methamphetamine rapidly decreases vesicular dopamine uptake.
Journal of neurochemistry 2000;74(5):2221-3.
2000: HM Haughey; Jeffrey M Brown; Diana G Wilkins; Glen R Hanson; Annette E Fleckenstein
Differential effects of methamphetamine on Na(+)/Cl(-)-dependent transporters.
Brain research 2000;863(1-2):59-65.
1999: Annette E Fleckenstein; HM Haughey; Ryan R Metzger; Jerry M Kokoshka; Evan Riddle; Jarom E Hanson; James W Gibb; Glen R Hanson
Differential effects of psychostimulants and related agents on dopaminergic and serotonergic transporter function.
European journal of pharmacology 1999;382(1):45-9.
1999: HM Haughey; Jeffrey M Brown; Annette E Fleckenstein; Glen R Hanson
Oxygen radicals differentially affect Na+/Cl(-)-dependent transporters.
European journal of pharmacology 1999;379(1):107-10.
1999: HM Haughey; Annette E Fleckenstein; Glen R Hanson
Differential regional effects of methamphetamine on the activities of tryptophan and tyrosine hydroxylase.
Journal of neurochemistry 1999;72(2):661-8.
1998: Jerry M Kokoshka; R A Vaughan; Glen R Hanson; Annette E Fleckenstein
Nature of methamphetamine-induced rapid and reversible changes in dopamine transporters.
European journal of pharmacology 1998;361(2-3):269-75.
1998: Jerry M Kokoshka; Ryan R Metzger; Diana G Wilkins; James W Gibb; Glen R Hanson; Annette E Fleckenstein
Methamphetamine treatment rapidly inhibits serotonin, but not glutamate, transporters in rat brain.
Brain research 1998;799(1):78-83.
1998: Glen R Hanson; James W Gibb; Ryan R Metzger; Jerry M Kokoshka; Annette E Fleckenstein
Methamphetamine-induced rapid and reversible reduction in the activities of tryptophan hydroxylase and dopamine transporters: oxidative consequences?
Annals of the New York Academy of Sciences 1998;844():103-7.
1998: Ryan R Metzger; Glen R Hanson; James W Gibb; Annette E Fleckenstein
3-4-Methylenedioxymethamphetamine-induced acute changes in dopamine transporter function.
European journal of pharmacology 1998;349(2-3):205-10.
1997: M P Gygi; Annette E Fleckenstein; James W Gibb; Glen R Hanson
Role of endogenous dopamine in the neurochemical deficits induced by methcathinone.
The Journal of pharmacology and experimental therapeutics 1997;283(3):1350-5.
1997: Annette E Fleckenstein; Diana G Wilkins; James W Gibb; Glen R Hanson
Interaction between hyperthermia and oxygen radical formation in the 5-hydroxytryptaminergic response to a single methamphetamine administration.
The Journal of pharmacology and experimental therapeutics 1997;283(1):281-5.
1997: Annette E Fleckenstein; Ryan R Metzger; M L Beyeler; James W Gibb; Glen R Hanson
Oxygen radicals diminish dopamine transporter function in rat striatum.
European journal of pharmacology 1997;334(1):111-4.
1997: Annette E Fleckenstein
Effect of methamphetamine on tryptophan hydroxylase activity: role of hyperthermia.
European journal of pharmacology 1997;332(3):263-5.
1997: Annette E Fleckenstein; Ryan R Metzger; Diana G Wilkins; James W Gibb; Glen R Hanson
Rapid and reversible effects of methamphetamine on dopamine transporters.
The Journal of pharmacology and experimental therapeutics 1997;282(2):834-8.
1997: Annette E Fleckenstein; M L Beyeler; J C Jackson; Diana G Wilkins; James W Gibb; Glen R Hanson
Methamphetamine-induced decrease in tryptophan hydroxylase activity: role of 5-hydroxytryptaminergic transporters.
European journal of pharmacology 1997;324(2-3):179-86.
1997: Annette E Fleckenstein; Ryan R Metzger; James W Gibb; Glen R Hanson
A rapid and reversible change in dopamine transporters induced by methamphetamine.
European journal of pharmacology 1997;323(2-3):R9-10.